HBM Holdings-B (02142) announces profit for the year is expected to be approximately $88 million to $95 million.

HBM HOLDINGS-B (02142) announced that it expects a profit between approximately 88 million US dollars (equivalent to about 685 million Hong Kong dollars) and 95 million US dollars (equivalent to about 739 million Hong Kong dollars) for the year ending December 31, 2025, compared to a profit of approximately 2.7 million US dollars for the year ending December 31, 2024. The expected adjusted profit is between 91 million US dollars (equivalent to about 708 million Hong Kong dollars) and 98 million US dollars (equivalent to about 763 million Hong Kong dollars). The expected increase in profit is mainly attributed to the continuous growth in the company's regular income, such as research collaborations with AstraZeneca and Pfizer based on platforms. The global partner network is expanding rapidly, as the income generated from innovative product licensing and collaborations has become a regular source of revenue for the company, such as licensing collaborations with Daiichi Sankyo, and licensing collaborations with Windward Bio. The rapid growth of Nona Bio's business, including revenue from technology licenses and platform-based services, as well as milestone payments from existing collaborations, such as research and technology licensing collaborations with Pfizer, are also contributing to the increase in profit.